

# Clinical trials of torcetrapib

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
<b>torcetrapib vs placebo</b>			
<b>RADIANCE 1 , 2007</b> [NCT00136981] n=450/454 follow-up: 24 months	atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy	patients with heterozygous familial hypercholesterolemia	Parallel groups open
<b>ILLUMINATE , 2007</b> [NCT00134264] n=7533/7534 follow-up: 1.52y	torcetrapib 60mg daily plus atorvastatin (at a dose established during the runinperiod) versus atorvastatin alone	patients at highcardiovascular risk	Parallel groups double blind 7 countries
<b>RADIANCE 2 , 2007</b> n=377/375 follow-up: 24 months	torcetrapib 60mg daily (on top of atorvastatin attitrated dose) versus placebo +atorvastatin attitrated dose	patients with mixed dyslipidaemia	Parallel groups double blind North America and Europe
<b>ILLUSTRATE , 2007</b> [NCT00134173] n=591/597 follow-up: 24 months	atorvastatin plus 60 mg of torcetrapib daily versus atorvastatin monotherapy	patients with coronary disease	Parallel groups open North America and Europe

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

## References

### **RADIANCE 1, 2007:**

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 Apr 19;356:1620-30 [17387131] [10.1056/NEJMoa071359](https://doi.org/10.1056/NEJMoa071359)

### **ILLUMINATE, 2007:**

Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 Nov 22;357:2109-22 [17984165] 10.1056/NEJMoa0706628

### **RADIANCE 2, 2007:**

Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60 [17630038]

### **ILLUSTRATE, 2007:**

Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzylo W, Bachinsky WB, Lasala GP, Tuzcu EM Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16 [17387129]

## 2 familial hypercholesterolemia

Trial	Treatments	Patients	Trials design and methods
<b>torcetrapib vs placebo</b>			
<b>RADIANCE 1 , 2007</b> [NCT00136981] n=450/454 follow-up: 24 months	atorvastatin combined with 60 mg of torcetrapib versus atorvastatin monotherapy	patients with heterozygous familial hypercholesterolemia	Parallel groups open

2

More details and results :

- cholesterol lowering intervention for familial hypercholesterolemia in all type of patients at <http://www.trialresultscenter.org/go-Q136>

## References

### **RADIANCE 1, 2007:**

Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 Apr 19;356:1620-30 [17387131] 10.1056/NEJMoa071359

Entry terms: torcetrapib, CP 529414, CP529414, CP-529414,